Background
Phase III RCT (POG 9412). Pediatric patients with high-risk B-precursor ALL. Compared augmented BFM chemotherapy with doxorubicin vs standard chemotherapy. Examined role of cranial RT dose reduction (18 Gy vs 24 Gy) in patients requiring cranial RT, and evaluated whether augmentation of maintenance therapy reduces CNS relapse risk in patients not receiving prophylactic cranial RT.
Interventions and follow up
Arm A: Augmented BFM + cranial RT 18 Gy (for CNS-positive or high-risk features) + IT chemotherapy
Arm B: Standard BFM + cranial RT 24 Gy (legacy dose) or no cranial RT + IT chemotherapy
Primary endpoint: EFS, CNS relapse rate
mFollow up: 5.0 year
Arm B: Standard BFM + cranial RT 24 Gy (legacy dose) or no cranial RT + IT chemotherapy
Primary endpoint: EFS, CNS relapse rate
mFollow up: 5.0 year
Results
5-yr EFS (augmented BFM): Superior to standard BFM in high-risk B-ALL
CNS relapse (18 Gy vs 24 Gy): No significant difference — 18 Gy non-inferior
Late neurocognitive outcomes: Improved with 18 Gy vs 24 Gy cranial RT
CNS relapse (18 Gy vs 24 Gy): No significant difference — 18 Gy non-inferior
Late neurocognitive outcomes: Improved with 18 Gy vs 24 Gy cranial RT
Adverse events
Main adverse events: Cranial RT 18 Gy: reduced neurocognitive effects vs 24 Gy; white matter changes on MRI. Augmented BFM: increased doxorubicin cumulative dose — cardiac monitoring required. Pegaspargase: allergy, pancreatitis, thrombosis.
Conclusions
Reduced-dose cranial RT (18 Gy) is equivalent to 24 Gy for CNS control in high-risk ALL with augmented systemic chemotherapy, with better neurocognitive outcomes. Augmented BFM improved disease control. Results informed subsequent trials reducing cranial RT indication to CNS-3 disease only.
Key Limitations
Key Limitations: Pre-MRD era trial; risk stratification did not incorporate end-induction MRD. Limited follow-up for cardiac toxicity from cumulative doxorubicin. Does not address question of complete RT elimination.
Clinical Context
POG 9412 contributed to the progressive reduction in cranial RT dose from 24 to 18 Gy in high-risk ALL, and ultimately supported the rationale for eliminating prophylactic cranial RT entirely in subsequent trials. Currently 18 Gy (or 12 Gy in some protocols) is used only for CNS-3 disease.
References
References: Nachman JB et al, Blood 2009 (POG 9412)